Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Colgate-Palmolive

McDonald's

We're reiterating three long ideas that recently reported calendar 1Q21 earnings. Amgen's pipeline provides a long runway for plenty of growth, though it's priced for permanent profit decline.

Q1 Earnings Reveal Plenty Of Upside In Amgen, McDonald's And Colgate-Palmolive

AbbVie

Here's why you should consider buying into these two companies for the long run.

2 Healthcare Stocks Perfect to Buy Now and Hold Until Retirement

THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m.

Amgen To Present AT the Cowen 2nd Annual Virtual Oncology Innovation Summit

THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4-8, 2021.

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021

I'm reiterating three Long Ideas that have underperformed the S&P 500 since my original reports: Amgen, Inc (AMGN), McDonald's Corporation (MCD), and Colgate-Palmolive Company (CL).

1Q21 Earnings Reveal Plenty Of Upside In Amgen, McDonald's And Colgate-Palmolive

Novartis

The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN) patents related to rheumatoid arthritis drug Enbrel, thus blocking Novartis AG's (NYSE: NVS) Sandoz from selling a biosimilar of the drug in the U.S. until 2029. The justices turned away Novartis subsidiary Sandoz Inc's appeal of a lower court decision that upheld the validity of the patents.

Supreme Court Rebuffs Novartis Appeal Over Amgen's Arthritis Drug Enbrel: Report

THOUSAND OAKS, Calif., May 13, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal NAVIGATOR Phase 3 trial demonstrating superiority across every primary and key secondary endpoint in a broad population of severe asthma patients, compared to placebo when added to standard of care (SoC).

New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients

THOUSAND OAKS, Calif., May 11, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha® (evolocumab) open label extension trial of patients living with HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular (CV) events, including complex revascularization procedures.

Efficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21

Emerson Electric

Honeywell

Hershey

Johnson & Johnson

Eli Lilly

Microsoft

Visa

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: May 11-24, 2021

AstraZeneca

THOUSAND OAKS, Calif., May 10, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma.

Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA

Albemarle

Gabelli Dividend & Income Trust

Financial Select Sector SPDR Fund

Everyone wants to be a contrarian investor. But in practice, most people buy more near tops and sell shares low.

5 Contrarian Dividend Stocks To Buy Now

THOUSAND OAKS, Calif., May 6, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m.

Amgen To Present At The 2021 Bank of America Merrill Lynch Healthcare Conference

THOUSAND OAKS, Calif., May 5, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.

FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis

There are certainly some problem spots for the big biotech.

Should Investors Worry About Amgen After Its Q1 Update?

Boeing

Intel

The near future looks concerning for these companies in three different sectors. But for long-term investors, that can create opportunities.

Is It Time to Buy the Dow Jones Industrials Average's 3 Worst-Performing Stocks of April?

Amgen's Q1 results didn't bode well with the investors and the stock plunged over 7% in Wednesday's trading session (April 28). But now that the stock has fallen 9% in just five days, will AMGN stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent?

Can Amgen Stock Rebound After The Recent 9% Fall?

Despite disappointing results that missed expectations, progress with an important new cancer drug saved the day.

This Is How Amgen Avoided a Catastrophic Q1 Update

Bristol-Myers

Moderna

Pfizer

SoFi Select 500 ETF

High-quality pharmaceutical stocks comes with steady business, low valuations and solid dividend. Let's look at a handful of them now.

7 Pharmaceutical Stocks To Buy For Valuation Plus Solid Dividends

Nobody seemed impressed by the company's latest quarterly results.

Why Amgen Stock Is Plummeting Today

Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.

Amgen (AMGN) Q1 Earnings, Sales Miss on Low Prices, Stock Down

Amgen Inc (NASDAQ: AMGN) has a rough start this year after its Q1 March-quarter revenue slipped 4% from the year-ago quarter, while its earnings fell about 10%. Earnings: Even though unit volumes grew 4% in the quarter, the revenue disappointment was primarily tied to lower prices.

Amgen Shares Drop On Light First Quarter Earnings Hit By Lower Prices

COVID-19 continued to negatively impact the big biotech.

Why Amgen's Q1 Results Disappointed Investors

THOUSAND OAKS, Calif., April 28, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing development program, a multi-center randomized clinical trial to compare the safety and efficacy of LUMAKRAS™ at 960 mg once daily versus a lower daily dose of the drug.

Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study

Amgen Inc. (AMGN) CEO Robert Bradway on Q1 2021 Results - Earnings Call Transcript

Amgen (AMGN) delivered earnings and revenue surprises of -7.50% and -5.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Amgen Stock (AMGN)